Stemline Therapeutics, Inc. (NASDAQ:STML) is one of the stocks that are taking the center stage today as the company shares are trading 8.19% or 0.56 points higher from last closing price of $6.84, reaching $7.4 at last check. So what’s going on with STML shares anyway? The price has risen in 2 of the last 5 days and is down -23.19% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -1,765,452 shares, and in total 926148 shares valued at $6.853 million were seen changing hands compared with 2.692 million shares valued at $18.411 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in STML stock for the next couple of days.

Stemline Therapeutics, Inc. (STML) shares have notched a 3-month decline of about -23.19%, but has still tumbled -35.65% year to date. By comparison, the stock sank -31.19% over the past 12 months, while it slipped -31.94% over the 1 month. The company’s market cap is around $358.28M, with its short interest ratio standing at 6.94%.

In the current trading session for STML, the stock witnessed two major price actions, it rose to a high of $7.47 and was down as much as $6.82 at one point. The high recorded is very low when compared to their 52-week high which is $6.01. The 52-week high is now at -59.9 distance from current price. Their recent low of $18.22 represents a 21.57% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for STML is $24.75, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Stemline Therapeutics, Inc. earned $-2.42 per share in the trailing 12 months and has a P/E ratio of -3.06. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 25.19 and lower compared to the sector’s average of 34.29. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. STML also has P/S multiple of 12.34. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.83x.

STML‘s last price was down -40.76% as compared to the average trading price of 50 days recorded at $12.49 while enlarging the period to 200 trading days, the average closing price was $10.25. At present, there are 52.38 million in the total number of common shares owned by the public and among those 45.59 million shares have been available to trade. The percentage of shares being held by the company management was 7.1% while institutions stake was 86.5%. The company has generated negative returns on equity over the last 12 months (-80.3%). It managed to keep its gross profit margin at 94.5% over the past 12 months.

When assessing the full upside of the STML stock, there is another set of technicals that should be looked into and considered. Its -27.32% decline from moving average of $10.18 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.37 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Stemline Therapeutics, Inc. — 7 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $24 on shares of Stemline Therapeutics, Inc. (NASDAQ:STML), which corresponds to 227.87% upside potential than its current market price of $7.4 and implies potential despite the recent advance in the price. However, their current target price has fallen from $26 a month ago and is down handily from the consensus target of $25.2 a quarter ago.

In the last five years, the EPS of the company has been roughly -5%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 47.8 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.